PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34596810-0	2021	Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways.	regorafenib	64-75	mechanistic target of rapamycin kinase	Homo sapiens	141-145	
34596810-12	2021	In addition, results revealed that our novel combination of catalpol and regorafenib showed potent synergistic anti-tumour effect via suppressing both of PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and their downstreams.	regorafenib	73-84	mechanistic target of rapamycin kinase	Homo sapiens	165-169	
34596810-13	2021	CONCLUSION: Catalpol and/or regorafenib markedly suppressed PI3K/p-Akt/mTOR/NF-kappaB and VEGF/VEGFR2 signaling pathways and consequently showed potent anti-tumour effects against HCC.	regorafenib	28-39	mechanistic target of rapamycin kinase	Homo sapiens	71-75	
32457362-0	2020	Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.	regorafenib	0-11	mechanistic target of rapamycin kinase	Homo sapiens	104-108	
33671452-7	2021	In vitro studies have also indicated that regorafenib could augment autophagy in myofibroblasts by suppressing TGF-beta1/mTOR (mechanistic target of rapamycin) signaling, and could promote apoptosis in myofibroblasts.	regorafenib	42-53	mechanistic target of rapamycin kinase	Homo sapiens	121-125	
33671452-7	2021	In vitro studies have also indicated that regorafenib could augment autophagy in myofibroblasts by suppressing TGF-beta1/mTOR (mechanistic target of rapamycin) signaling, and could promote apoptosis in myofibroblasts.	regorafenib	42-53	mechanistic target of rapamycin kinase	Homo sapiens	127-158	
32457362-7	2020	Regorafenib treatment inhibits known receptor tyrosine kinase targets RET and PDGFRbeta and intracellular signalling through the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.	regorafenib	0-11	mechanistic target of rapamycin kinase	Homo sapiens	148-152	
29783729-8	2018	The mechanisms underlying the positive effects of combining CGA and Regorafenib were also addressed and an increased inhibition of MAPK (mitogen-activated protein kinase)and PI3K/Akt/mTORC (phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling was observed.	regorafenib	68-79	mechanistic target of rapamycin kinase	Homo sapiens	239-268	
29783729-8	2018	The mechanisms underlying the positive effects of combining CGA and Regorafenib were also addressed and an increased inhibition of MAPK (mitogen-activated protein kinase)and PI3K/Akt/mTORC (phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling was observed.	regorafenib	68-79	mechanistic target of rapamycin kinase	Homo sapiens	183-187	
28978118-6	2017	The combined treatment with regorafenib and silybin induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/mTOR intracellular pathway.	regorafenib	28-39	mechanistic target of rapamycin kinase	Homo sapiens	134-138	
29609689-6	2018	Moreover, the activation of Akt/mTOR signaling was inhibited by regorafenib pre-incubation.	regorafenib	64-75	mechanistic target of rapamycin kinase	Homo sapiens	32-36	
28166200-8	2017	Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR.	regorafenib	127-138	mechanistic target of rapamycin kinase	Homo sapiens	227-231